Understand the source comparison
Peptide Neuroprotection: Research Models vs Clinical Application
P21 (CNTF fragment) NMDA receptor modulation, excitotoxicity reduction 40% infarct volume reduction in MCAO rodent stroke models (J Neurosci, 2015) Requires intranasal or intracerebroventricular delivery. Negligible systemic BBB crossing No human trials. Resea
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- P21 (CNTF fragment)
- NMDA receptor modulation, excitotoxicity reduction
- 40% infarct volume reduction in MCAO rodent stroke models (J Neurosci, 2015)
- Requires intranasal or intracerebroventricular delivery. Negligible systemic BBB crossing
- No human trials. Research-grade only
- Strong mechanistic data, delivery route limits human applicability
- Dihexa
- BDNF-TrkB pathway potentiation, dendritic spine restoration
- Restored hippocampal spine density to wild-type in APP/PS1 mice; improved spatial memory 60% vs controls (Neurobiol Aging, 2015)
- High lipophilicity allows passive BBB diffusion. Brain:plasma ratio 4:1 at 2h
- Phase I completed, no published Phase II data
- Most promising BBB-penetrant candidate, lacks large-scale safety data
- Cerebrolysin
- Neurotrophin-mimetic activity, microglial M2 polarization
- Reduced IL-1beta 50% and improved Morris maze 60% in rat TBI model (J Neurotrauma, 2016)
- Mixed. Contains peptides <10kDa with variable permeability
- Approved in 44 countries for stroke/TBI; U.S. regulatory status unclear
- Extensive clinical use outside U.S., batch variability concerns
- Thymalin
- Antioxidant enzyme upregulation (SOD, GPx)
- Restored GPx to young-adult levels in aged rats, reduced lipid peroxidation 35% (Biogerontology, 2018)
- Minimal BBB crossing. Peripheral immune modulation predominates
- No CNS-specific trials. Used for immune senescence research
- Indirect neuroprotection via systemic antioxidant support, not direct CNS targeting
- The table underscores a critical gap: peptides help with neuroprotection in controlled injury models, but translating those effects to human CNS disease requires solving delivery, dosing, and bioavailability challenges that most preclinical studies don't address.